Improved glycaemic control and less hypoglycaemia with insulin glargine compared with NPH insulin in patients with type 2 diabetes leads to fewer long-term complications -: Results of the Diabetes Mellitus Simulation Model

被引：0
|
作者：
Maxion-Bergemann, S
Müller, E
Bergemann, R
Walleser, S
Huppertz, E
机构：
[1] Inst Med Outcome Res, Lorrach, Germany
[2] Aventis Pharma Deutschland GMBH, Bad Soden am Taunus, Germany
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61725-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：674 / 675
页数：2
相关论文
共 50 条
  • [1] Improved glycaemic control and reduced nocturnal hypoglycaemia in patients with Type 2 diabetes with morning administration of insulin glargine compared with NPH insulin
    Fritsche, A
    Schweitzer, MA
    Häring, H
    [J]. DIABETOLOGIA, 2002, 45 : A52 - A52
  • [2] Long-term glycaemic control with insulin glargine in Type 2 diabetes
    Kacerovsky-Bielesz, G
    Dressler, A
    Freunscht, R
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 71 (02) : 184 - 191
  • [3] Cost-effectiveness analysis of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the diabetes mellitus model in patients with Type 2 diabetes in Switzerland
    Brändle, M
    Russ, W
    Greiner, RA
    [J]. DIABETOLOGIA, 2004, 47 : A343 - A344
  • [4] Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin
    Porcellati, F
    Rossetti, P
    Pampanelli, S
    Fanelli, CG
    Torlone, E
    Scionti, L
    Perriello, G
    Bolli, GB
    [J]. DIABETIC MEDICINE, 2004, 21 (11) : 1213 - 1220
  • [5] Insulin glargine is associated with less hypoglycaemia than NPH insulin in older patients with Type 2 diabetes
    Riddle, M
    Massi-Benedetti, M
    Häring, HU
    Dailey, G
    Murray, F
    Lin, Z
    Rosenstock, J
    [J]. DIABETOLOGIA, 2004, 47 : A328 - A328
  • [6] Long-Term Outcomes of Analogue Insulin Compared With NPH for Patients With Type 2 Diabetes Mellitus
    Prentice, Julia C.
    Conlin, Paul R.
    Gellad, Walid F.
    Edelman, David
    Lee, Todd A.
    Pizer, Steven D.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2015, 21 (03): : E235 - U78
  • [7] Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland
    Braendle, M.
    Azoulay, M.
    Greiner, R.-A.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (04) : 203 - 220
  • [8] Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin
    Dailey, G. E.
    Gao, L.
    Aurand, L.
    Garg, S. K.
    [J]. DIABETES OBESITY & METABOLISM, 2013, 15 (12): : 1085 - 1092
  • [9] Treatment to target in Type 2 diabetes: successful glycaemic control with less nocturnal hypoglycaemia with insulin glargine versus NPH insulin added to oral therapy
    Riddle, M
    Rosenstock, J
    [J]. DIABETOLOGIA, 2002, 45 : A52 - A52
  • [10] Lower rate of hypoglycaemia but comparable glycaemic control with insulin detemir compared to NPH insulin in patients with type 1 diabetes
    Hermansen, K.
    Heller, S.
    Andersen, M.
    Russell-Jones, D. L.
    [J]. DIABETOLOGIA, 2009, 52 : S359 - S359
12345